---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-013236"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T05:12:26.330955+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Allarity presents novel DRP for daratumumab in multiple myeloma at AACR

## Summary
- First DRP developed for an antibody therapy (daratumumab), expanding platform beyond small molecules.
- DRP identified 53 genes (27 sensitivity, 26 resistance) from in vitro data and KYDAR trial bone marrow samples.
- Predictor aims to identify multiple myeloma patients likely to benefit from daratumumab; presented at AACR 2025.
- Management highlights potential for future collaborations to bring precision diagnostics to more patients.
- Allarity's lead program, stenoparib (dual PARP/WNT inhibitor), remains in Phase 2 for ovarian cancer and small cell lung cancer.

## SEC filing metadata
- accession: 0001437749-25-013236
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774925013236/0001437749-25-013236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774925013236/allr20250425_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-013236
- JSON: https://secwatch.observer/filing/0001437749-25-013236.json
- Plain text: https://secwatch.observer/filing/0001437749-25-013236.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.